eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
08 mars 2023 16h01 HE
|
eFFECTOR Therapeutics, Inc.
Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received...
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
21 févr. 2023 08h30 HE
|
eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
30 janv. 2023 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update
05 janv. 2023 16h01 HE
|
eFFECTOR Therapeutics, Inc.
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib...
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
07 nov. 2022 16h00 HE
|
eFFECTOR Therapeutics, Inc.
- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
31 oct. 2022 14h05 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”)...
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
26 oct. 2022 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”)...
eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer
26 sept. 2022 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”)...
eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference
21 sept. 2022 09h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”)...
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
14 sept. 2022 08h00 HE
|
eFFECTOR Therapeutics, Inc.
- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 - - Drug levels achieved with sub-cutaneous formulation equivalent to...